RecruitingACTRN12623001178639

A prospective pilot study of biofeedback training with “Contrain” in patients with major Low Anterior Resection Syndrome (LARS) and faecal incontinence symptoms after anterior resection for rectal cancer

A prospective pilot study of biofeedback training with “Contrain” in patients with major LARS and faecal incontinence symptoms after anterior resection for rectal cancer


Sponsor

University of Otago

Enrollment

20 participants

Start Date

Oct 10, 2023

Study Type

Interventional

Conditions

Summary

This study is evaluating the efficacy of delivering pelvic floor physiotherapy using biofeedback and electrical stimulation techniques to help re-train the rectal muscles and improve faecal continence. Who is it for? You may be eligible for this study if you are aged 18 to 80 years old, and have major low anterior resection syndrome (LARS) after surgery for rectal cancer. Study details Participants will choose to either receive pelvic floor biofeedback stimulation or standard care. Pelvic floor biofeedback stimulation will involve using the Contrain multifunction trainer for up to two 20-minute sessions per day for nine months. Participants will be asked to complete questionnaires on their faecal incontinence symptoms and quality of life over the course of the nine-month study period. It is hoped that results from this pilot study will help determine the feasibility of pelvic floor biofeedback stimulation after rectal cancer surgery, to help develop a larger study in the future.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Plain Language Summary

Simplified for easier understanding

After surgery for rectal cancer, many people experience a cluster of bowel problems known as Low Anterior Resection Syndrome (LARS) — including urgency, frequent trips to the toilet, leakage, and difficulty controlling bowel movements. These symptoms can have a serious impact on quality of life. This pilot study is testing whether a pelvic floor biofeedback device called Contrain can help retrain the rectal muscles and improve bowel control. Participants choose between receiving the biofeedback treatment or continuing with standard care. The biofeedback program involves using the Contrain device for up to two 20-minute sessions per day over nine months. Questionnaires about symptoms and quality of life are completed throughout the study period. You may be eligible if you are aged 18 to 80, have had surgery for rectal cancer, have major LARS (confirmed by a score above 30), and your bowel has been reconnected for at least a year. You should be motivated and available to commit to regular sessions over the study period. This study could pave the way for a larger trial proving biofeedback's effectiveness.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Each participant allocated to treatment will be given a training programme with the Contrain® multifunction trainer (Procon GmbH, Hamburg, Germany). Patients will undergo two 20-minute sessions per da

Each participant allocated to treatment will be given a training programme with the Contrain® multifunction trainer (Procon GmbH, Hamburg, Germany). Patients will undergo two 20-minute sessions per day for nine months, with encouragement to do this morning and evening. The initial session is supervised by a physiotherapist, and subsequent sessions are performed at home, with remote support from the study’s physiotherapist as required. The participant will be asked to perform exercises while standing, with the probe inserted into their anus or with skin pads surrounding the anus depending on patient preference. They will select the routines and intensity of the electrical stimulation. The Contrain gives immediate on-screen feedback, which includes clearly documenting the strength of the contraction of the pelvic floor and anal sphincters. Feedback on contraction strength is given in microvolts, and participants are encouraged to contract at >80% of their capacity, which is determined by maximal contractions with the device. This will assist participants to correctly perform the exercises as they can see what their values are. In certain routines the timing of the electrical stimulation can be co-ordinated with the electromyography (EMG) readings to help increase the strength of the maximal achieved muscle contraction, as well as improve neurological feedback to the brain. This is known as "triple target therapy", combining biofeedback, stimulation, and pelvic floor exercises. The number of exercises per day, and the performance in each exercise, will be recorded by the Contrain device. In addition to this, an intermittent clinical review (once every three months, for 30 minutes a session) will be performed by the study’s physiotherapist. At this time the performance in terms of frequency of exercise sessions and improvement in the strength of contraction will be reviewed. The ability of the participant to coordinate contraction, as well as relax the pelvic floor on bearing down, will also be reviewed. During the intervention, participants will not receive pelvic floor physiotherapy.


Locations(1)

otago, New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12623001178639


Related Trials